{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:27:01Z","timestamp":1767626821284,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2022CR29","2023HQ11"],"award-info":[{"award-number":["2022CR29","2023HQ11"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","meddos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Dosimetry"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.meddos.2023.06.003","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T08:13:21Z","timestamp":1691482401000},"page":"41-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-8463","authenticated-orcid":false,"given":"Ming-Wei","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Shen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Shu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meddos.2023.06.003_bib0001","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.meddos.2023.06.003_bib0002","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.meddos.2023.06.003_bib0003","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.3390\/curroncol29100619","article-title":"Outcomes of high-dose stereotactic ablative radiotherapy to all\/multiple sites for oligometastatic renal cell cancer patients","volume":"29","author":"Ma","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0000000000000622","article-title":"Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"43","author":"He","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0006","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0007","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0008","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2021.066","article-title":"Physical and biological characteristics of particle therapy for oncologists","volume":"53","author":"Byun","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.meddos.2023.06.003_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.833364","article-title":"Imaging strategies in proton therapy for thoracic tumors: a mini review","volume":"12","author":"Algranati","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0010","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.meddos.2023.06.003_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.meddos.2023.06.003_bib0012","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0013","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0014","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.21873\/invivo.12116","article-title":"Proton therapy for primary renal cell carcinoma: the first nationwide retrospective study in Japan","volume":"34","author":"Fukumitsu","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.meddos.2023.06.003_bib0015","article-title":"Institutional experience of using active breathing control for paediatric and teenage patients receiving thoraco-abdominal radiotherapy","volume":"39","author":"Gough","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.meddos.2023.06.003_bib0016","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ijrobp.2006.11.008","article-title":"Active breathing control for Hodgkin's disease in childhood and adolescence: feasibility, advantages, and limits","volume":"67","author":"Claude","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Medical Dosimetry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958394723000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958394723000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:32:54Z","timestamp":1760693574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958394723000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["S0958394723000626"],"URL":"https:\/\/doi.org\/10.1016\/j.meddos.2023.06.003","relation":{},"ISSN":["0958-3947"],"issn-type":[{"type":"print","value":"0958-3947"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report","name":"articletitle","label":"Article Title"},{"value":"Medical Dosimetry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meddos.2023.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American Association of Medical Dosimetrists.","name":"copyright","label":"Copyright"}]}}